Imiquimod

Displaying 1 - 2 of 2CSV
Yoon, A. J., Carvajal, R. D., Graboyes, E. M., Kaczmar, J. M., Albergotti, W. G., Kejner, A. E., Troob, S. H., Philipone, E., Anoma, J.-S., Armeson, K. E., Hill, E. G., Richardson, M. S., Woods, T. R., Chera, B. S., Nourollah-Zadeh, F., Lee, B. J., Pandruvada, S., Kourtidis, A., Kingsley, C., … Newman, J. G. (2025). Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1530262
Publication Date
Columbia Affiliation
Satish, T., Khan, S., Levin, M., Carvajal, R., & Yoon, A. J. (2021). Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission. Journal for ImmunoTherapy of Cancer, 9(10), e001219. https://doi.org/10.1136/jitc-2020-001219
Publication Date